BTIG Research Reiterates “Buy” Rating for MDxHealth (NASDAQ:MDXH)

MDxHealth (NASDAQ:MDXH)‘s stock had its “buy” rating reiterated by BTIG Research in a note issued to investors on Tuesday,Benzinga reports. They presently have a $7.00 price target on the stock. BTIG Research’s price objective would suggest a potential upside of 101.15% from the stock’s current price.

Other analysts have also issued research reports about the stock. TD Cowen raised their price target on shares of MDxHealth from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of MDxHealth in a research note on Wednesday, October 8th. Wall Street Zen upgraded MDxHealth to a “hold” rating in a research report on Saturday, August 30th. Finally, Lake Street Capital upped their price target on MDxHealth from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.75.

MDxHealth Stock Performance

MDxHealth stock opened at $3.48 on Tuesday. The stock has a 50-day simple moving average of $3.86 and a 200 day simple moving average of $3.35. The stock has a market capitalization of $164.57 million, a price-to-earnings ratio of -5.44 and a beta of 1.59. The company has a quick ratio of 1.02, a current ratio of 1.14 and a debt-to-equity ratio of 13.81. MDxHealth has a 12-month low of $1.35 and a 12-month high of $5.33.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 30.50%.The company had revenue of $27.43 million for the quarter, compared to the consensus estimate of $24.11 million. On average, research analysts anticipate that MDxHealth will post -1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in MDXH. Hudson Bay Capital Management LP bought a new position in shares of MDxHealth in the 3rd quarter worth $70,000. Susquehanna International Group LLP acquired a new position in MDxHealth in the third quarter valued at about $264,000. Qube Research & Technologies Ltd bought a new position in MDxHealth during the third quarter worth about $144,000. Mink Brook Asset Management LLC bought a new position in MDxHealth during the third quarter worth about $743,000. Finally, Millennium Management LLC acquired a new position in shares of MDxHealth during the 3rd quarter worth about $127,000.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.